The Survey of Satisfaction in Chinese Rheumatologists and Patients With Rheumatoid Arthritis

A questionnaire for this research is designed, which initiated from TSQM-II treatment satisfaction questionnaire and based on research launched by rheumatology and immunology departments of Chinese 12 public tertiary hospitals distributed directionally by Chinese Rheumatism Data Center (CRDC). The research is about treatment satisfaction and its influencing factors for Chinese rheumatoid immunologists and rheumatoid arthritis (RA) patients as well as their expectations for treating this disease. This research will explore the matching degree between treatment satisfaction and expectation about rheumatoid arthritis from doctors and patients.

Study Overview

• Status: Completed
• Conditions: Rheumatoid Arthritis; Satisfaction
• Intervention / Treatment: Other: TSQM-II

Detailed Description

In the last decade, China has made quick progress on treatment of rheumatoid arthritis. However, the improvement of remission rate cannot fully represent needs of patients for health. To meet health demands of patients and improve their satisfaction, an efficacy evaluation system based on the outcome report of patients should be established. A questionnaire for this research is designed and mended in view of TSQM-II treatment satisfaction questionnaire and the actual situation of RA diagnosis and treatment in China. An investigation on treatment satisfaction and its influencing factors for Chinese rheumatoid immunologists and rheumatoid arthritis (RA) patients as well as their expectations for this disease is carried out based on 120 rheumatoid immunologists and 1,200 rheumatoid arthritis patients (1:10) from Chinese 12 public tertiary hospitals distributed directionally by Chinese Rheumatism Data Center (CRDC). The research concludes rheumatoid specialist physicians for doctor population, and persons aged over 18 for patient population who has been confirmed as RA for 6 months above, excluding patients with Chinese reading comprehension barriers or without any RA treatment. Finally, summarize and analyze the total score of satisfaction from doctors and patients, average score of doctors and patients for various medical demands, as well as the satisfaction of patients about communication and service during medical treatment.

• Study Type: Observational
• Enrollment (Actual): 1365

Contacts and Locations

• Study Contact: Name: Mengtao Li, MD; Phone Number: +86-10-65296114; Email: mengtao.li@cstar.org.cn
• Study Contact Backup: Name: Nan Jiang, MD; Phone Number: +86-10-65124875; Email: jn_pumc@163.com

Study Locations

• China
  • Beijing, China, 100730
    • Peking Union Medical College Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Subjects come from 12 hospitals in Chinese Rheumatism Data Center.

Description

Inclusion Criteria:

Doctors - registered rheumatoid specialist physicians subordinated to the 12 designated hospitals Patients - aged over 18, confirming RA for more than 6 months

Exclusion Criteria:

Doctors - N/A Patients - with Chinese reading comprehension barriers (unable to complete the questionnaire independently), without any RA treatment

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
rheumatologists; Inclusion criteria: Registered rheumatoid specialist physicians subordinated to the 12 designated hospitals The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in rheumatologists.	Other: TSQM-II; Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups
patients; Inclusion criteria: Aged over 18, confirming RA for more than 6 months Exclusion criteria. Patients with Chinese reading comprehension barriers (unable to complete the questionnaire independently), without any RA treatment The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in patients.	Other: TSQM-II; Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total score of patient satisfaction	Total score of patient satisfaction	1 day

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Average score of patients for various treatment demands	Average score of patients for various treatment demands	1 day
Average score of patients for long-term treatment demands	Average score of patients for long-term treatment demands	1 day
Average score of patients for new drug demands	Average score of patients for new drug demands	1 day
Total score of doctor satisfaction	Total score of doctor satisfaction	1 day
Average score of doctors for various treatment demands	Average score of doctors for various treatment demands	1 day
Average score of doctors for long-term treatment demands	Average score of doctors for long-term treatment demands	1 day
Average score of doctors for new drug demands	Average score of doctors for new drug demands	1 day

Collaborators and Investigators

• Sponsor: Chinese SLE Treatment And Research Group
• Investigators: Study Chair: Xiaofeng Zeng, Doctor, Director of Rheumatology and Immunology Department Chinese Academy of Medical Sciences &Peking Union Medical College Hospital

Study record dates

Study Major Dates

• Study Start (Actual): March 31, 2018
• Primary Completion (Actual): April 30, 2018
• Study Completion (Actual): April 30, 2018

Study Registration Dates

• First Submitted: March 21, 2018
• First Submitted That Met QC Criteria: March 25, 2018
• First Posted (Actual): March 30, 2018

Study Record Updates

• Last Update Posted (Actual): August 31, 2023
• Last Update Submitted That Met QC Criteria: August 29, 2023
• Last Verified: March 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid
• Other Study ID Numbers: CRDC-satisfaction

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No